NFE2L2 and cancer: While the interaction between AMPK and NRF2 is context dependent, pharmacological activation of AMPK can limit growth signals and sensitize tumors: metformin has been shown to suppress NRF2-mediated chemoresistance and attenuate HO-1/antioxidant responses in cancer models [83,96].